Chiang Ching-Hsiang, Kuo Hann-Chorng
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.
Front Pharmacol. 2022 Feb 8;13:847520. doi: 10.3389/fphar.2022.847520. eCollection 2022.
This study investigated the therapeutic effect of repeated urethral sphincter injections of autologous platelet-rich plasma (PRP) in treatment of stress urinary incontinence (SUI) in women due to intrinsic sphincter deficiency (ISD) refractory to medical treatment or after the first anti-incontinence surgery. Twenty-six women with SUI due to urodynamically proven ISD were prospectively enrolled. Five milliliters of PRP (2.5-5 times of the platelet concentrations in peripheral blood) were injected into the external sphincter at 5 sites, with 4 treatments at monthly interval. The primary end-point was post-treatment Global Response Assessment (GRA, scored 0-3) score after four PRP treatments. A GRA ≥ 2 was considered as a successful result. The secondary endpoints included changes in visual analog scale (VAS) of SUI and urodynamic parameters. The follow-up date was 12 months after the fourth PRP treatment. The mean age was 61.7 ± 15.3 years. The overall success rate was 50% with the post-treatment mean GRA of 1.5 ± 1.1. Complete dryness was achieved in 12 patients (46.2%) after the PRP treatment, and 7 (26.9%) kept total continence at 12 months. The mean VAS of SUI score decreased significantly from 6.4 ± 2.3 to 3.9 ± 2.3 after treatment ( < 0.001). The abdominal leak point pressure increased significantly from 117.5 ± 63.8 to 133.6 ± 61.7 cmHO ( = 0.045). No perioperative adverse events or severe complications occurred, except 1 (3.8%) patient reported straining to void which was self-limited. Repeated urethral sphincter injections of autologous PRP are a safe procedure that provides significant reduction in the severity of female SUI and a mid-term durability, suggesting PRP treatment is effective to increase urethral sphincter resistance for female SUI.
本研究调查了重复尿道括约肌注射自体富血小板血浆(PRP)对因内在括约肌功能缺陷(ISD)导致的女性压力性尿失禁(SUI)的治疗效果,这些患者药物治疗无效或在首次抗尿失禁手术后仍存在问题。前瞻性纳入了26例经尿动力学证实因ISD导致SUI的女性患者。将5毫升PRP(外周血血小板浓度的2.5 - 5倍)在5个部位注入外括约肌,每月治疗1次,共治疗4次。主要终点是4次PRP治疗后的治疗后整体反应评估(GRA,评分0 - 3)得分。GRA≥2被认为是成功结果。次要终点包括SUI视觉模拟量表(VAS)和尿动力学参数的变化。随访日期为第4次PRP治疗后12个月。平均年龄为61.7±15.3岁。总体成功率为50%,治疗后平均GRA为1.5±1.1。PRP治疗后12例患者(46.2%)实现完全干燥,7例(26.9%)在12个月时保持完全控尿。治疗后SUI的平均VAS评分从6.4±2.3显著降至3.9±2.3(<0.001)。腹部漏尿点压力从117.5±63.8显著增加至133.6±61.7 cmH₂O(P = 0.045)。除1例(3.8%)患者报告排尿困难且为自限性外,未发生围手术期不良事件或严重并发症。重复尿道括约肌注射自体PRP是一种安全的方法,可显著降低女性SUI的严重程度并具有中期持久性,表明PRP治疗可有效增加女性SUI患者的尿道括约肌阻力。